At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 90 enrolled
Drug / intervention
Indacaterol +1 moredrug
Likely dose
Indacaterol 150 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12 Week, Multi-center, Randomized, Open Label Study, eValuating the Efficacy and Safety of Treatment Regimens That Include ONbrez (Indacaterol) in Patients With Moderate to Severe COPD (MOVE-ON Study)
In Brief
A Phase 3 clinical trial evaluating Indacaterol and Long-acting beta2-agonist for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 90 participants across 8 sites.
Detailed Summary
In this 12-week study, patients were randomized to either open-label indacaterol or standard of care for Chronic Obstructive Pulmonary Disease (COPD) treatment; efficacy and safety were assessed.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesIsrael
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2010
Enrollment StartMar 2011
Primary CompletionMay 2012
TodayJul 2026
First PostedNov 2, 2010
Enrollment StartMar 1, 2011
Primary CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 15.7 years ago
Interventions
Indacateroldrug
Indacaterol 150 µg once-daily via single-dose dry powder inhaler
Long-acting beta2-agonistdrug
Long-acting beta2-agonist (LABA) bronchodilator monotherapy via inhaler twice daily